Barbosa, Bruna Renata Dutra; Barbosa, Sávio Fujita; Tavares, Guilherme Diniz; Bou-Chacra, Nadia Araci 
; Pinto, Terezinha de Jesus Andreoli
Source: Brazilian Journal of Pharmaceutical Sciences. Unidade: FCF
Assunto: DEGENERAÇÃO MACULAR (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARBOSA, Bruna Renata Dutra et al. Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration. Brazilian Journal of Pharmaceutical Sciences, v. 50, n. 1, p. 64-72, 2014Tradução . . Disponível em: https://doi.org/10.1590/s1984-82502011000100006. Acesso em: 15 out. 2024.APA
Barbosa, B. R. D., Barbosa, S. F., Tavares, G. D., Bou-Chacra, N. A., & Pinto, T. de J. A. (2014). Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration. Brazilian Journal of Pharmaceutical Sciences, 50( 1), 64-72. doi:10.1590/s1984-82502011000100006NLM
Barbosa BRD, Barbosa SF, Tavares GD, Bou-Chacra NA, Pinto T de JA. Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2014 ; 50( 1): 64-72.[citado 2024 out. 15 ] Available from: https://doi.org/10.1590/s1984-82502011000100006Vancouver
Barbosa BRD, Barbosa SF, Tavares GD, Bou-Chacra NA, Pinto T de JA. Critical evaluation of the off-label indication and of the risks associated to the use of multi-dose vials on the treatment of age-related macular degeneration [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2014 ; 50( 1): 64-72.[citado 2024 out. 15 ] Available from: https://doi.org/10.1590/s1984-82502011000100006
